CBL is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Feb 4

PMID 20126411

Citations 61

Authors

Yi-Hung Carol Tan

Soundararajan Krishnaswamy

Suvobroto Nandi

Rajani Kanteti

Sapana Vora

Kenan Onel

Rifat Hasina

Fang-Yi LO

Essam El-Hashani

Gustavo Cervantes

Matthew Robinson

Han-Shui Hsu

Stephen C Kales

Stanley Lipkowitz

Theodore Karrison

Martin Sattler

Everett E Vokes

Yi-Ching Wang

Ravi Salgia

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) is a heterogeneous group of disorders with a number of genetic and proteomic alterations. c-CBL is an E3 ubiquitin ligase and adaptor molecule important in normal homeostasis and cancer. We determined the genetic variations of c-CBL, relationship to receptor tyrosine kinases (EGFR and MET), and functionality in NSCLC.

Methods And Findings: Using archival formalin-fixed paraffin embedded (FFPE) extracted genomic DNA, we show that c-CBL mutations occur in somatic fashion for lung cancers. c-CBL mutations were not mutually exclusive of MET or EGFR mutations; however they were independent of p53 and KRAS mutations. In normal/tumor pairwise analysis, there was significant loss of heterozygosity (LOH) for the c-CBL locus (22%, n = 8/37) and none of these samples revealed any mutation in the remaining copy of c-CBL. The c-CBL LOH also positively correlated with EGFR and MET mutations observed in the same samples. Using select c-CBL somatic mutations such as S80N/H94Y, Q249E and W802* (obtained from Caucasian, Taiwanese and African-American samples, respectively) transfected in NSCLC cell lines, there was increased cell viability and cell motility.

Conclusions: Taking the overall mutation rate of c-CBL to be a combination as somatic missense mutation and LOH, it is clear that c-CBL is highly mutated in lung cancers and may play an essential role in lung tumorigenesis and metastasis.

Citing Articles

An Observatory for the Oncogene: A Guide for Targeted Therapies.

Altintas D, Comoglio P Cancers (Basel). 2023; 15(18).

PMID: 37760640 PMC: 10526818. DOI: 10.3390/cancers15184672.

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.

He K, Berz D, Gadgeel S, Iams W, Bruno D, Blakely C J Thorac Oncol. 2023; 18(7):907-921.

PMID: 36842467 PMC: 10330304. DOI: 10.1016/j.jtho.2023.02.016.

The RING finger protein family in health and disease.

Cai C, Tang Y, Zhai J, Zheng C Signal Transduct Target Ther. 2022; 7(1):300.

PMID: 36042206 PMC: 9424811. DOI: 10.1038/s41392-022-01152-2.

Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential.

Erdrich J, Lourdault K, Judd A, Kaufman D, Gong K, Gainsbury M J Surg Res. 2022; 279:682-691.

PMID: 35940046 PMC: 9549765. DOI: 10.1016/j.jss.2022.06.031.

MET∆14 promotes a ligand-dependent, AKT-driven invasive growth.

Cerqua M, Botti O, Arigoni M, Gioelli N, Serini G, Calogero R Life Sci Alliance. 2022; 5(10).

PMID: 35636967 PMC: 9152130. DOI: 10.26508/lsa.202201409.

References

Miyake S, Lill N, Douillard P, Band H . Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem. 1999; 274(23):16619-28. DOI: 10.1074/jbc.274.23.16619. View

Dunbar A, Gondek L, OKeefe C, Makishima H, Rataul M, Szpurka H . 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008; 68(24):10349-57. PMC: 2668538. DOI: 10.1158/0008-5472.CAN-08-2754. View

Clague M, Urbe S . The interface of receptor trafficking and signalling. J Cell Sci. 2001; 114(Pt 17):3075-81. DOI: 10.1242/jcs.114.17.3075. View

Burke P, SCHOOLER K, Wiley H . Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001; 12(6):1897-910. PMC: 37350. DOI: 10.1091/mbc.12.6.1897. View

Rao N, Dodge I, Band H . The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol. 2002; 71(5):753-63. View

Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L . MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-7. PMC: 2409244. DOI: 10.1073/pnas.0710370104. View

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. DOI: 10.1126/science.1141478. View

Naramura M, Kole H, Hu R, Gu H . Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A. 1998; 95(26):15547-52. PMC: 28080. DOI: 10.1073/pnas.95.26.15547. View

Meisner H, Czech M . Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J Biol Chem. 1995; 270(43):25332-5. DOI: 10.1074/jbc.270.43.25332. View

10.

Hirsch D, Shen Y, Wu W . Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res. 2006; 66(7):3523-30. DOI: 10.1158/0008-5472.CAN-05-1547. View

11.

Thien C, Langdon W . EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene. Oncogene. 1997; 14(18):2239-49. DOI: 10.1038/sj.onc.1201193. View

12.

Grand F, Hidalgo-Curtis C, Ernst T, Zoi K, Zoi C, McGuire C . Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009; 113(24):6182-92. DOI: 10.1182/blood-2008-12-194548. View

13.

Zheng N, Wang P, Jeffrey P, Pavletich N . Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 2000; 102(4):533-9. DOI: 10.1016/s0092-8674(00)00057-x. View

14.

Reindl C, Quentmeier H, Petropoulos K, Greif P, Benthaus T, Argiropoulos B . CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009; 15(7):2238-47. DOI: 10.1158/1078-0432.CCR-08-1325. View

15.

Caligiuri M, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky K . Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood. 2007; 110(3):1022-4. PMC: 1924768. DOI: 10.1182/blood-2006-12-061176. View

16.

Kozlov G, Peschard P, Zimmerman B, Lin T, Moldoveanu T, Mansur-Azzam N . Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase. J Biol Chem. 2007; 282(37):27547-27555. DOI: 10.1074/jbc.M703333200. View

17.

Shtiegman K, Kochupurakkal B, Zwang Y, Pines G, Starr A, Vexler A . Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 2007; 26(49):6968-78. DOI: 10.1038/sj.onc.1210503. View

18.

Meng W, Sawasdikosol S, Burakoff S, Eck M . Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature. 1999; 398(6722):84-90. DOI: 10.1038/18050. View

19.

Lill N, Douillard P, Awwad R, Ota S, Lupher Jr M, Miyake S . The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem. 2000; 275(1):367-77. DOI: 10.1074/jbc.275.1.367. View

20.

Sanada M, Suzuki T, Shih L, Otsu M, Kato M, Yamazaki S . Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009; 460(7257):904-8. DOI: 10.1038/nature08240. View